Medication Possession Ratio Associated with Short-Term Virologic Response in Individuals Initiating Antiretroviral Therapy in Namibia

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hong, Steven Y ^a,b   Jerger, Logan ^b   Jonas, Anna ^c   Badi, Alfons ^c   Cohen, Steven ^b   Nachega, Jean B ^d,e   Parienti, Jean Jacques ^f   Tang, Alice M ^b   Wanke, Christine ^a,b   Terrin, Norma ^a   Pereko, Dawn ^g   Blom, Abraham ^c   Trotter, Andrew B ^a,b   Jordan, Michael R ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ministry of Health and Social Services   (Namibia)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF STELLENBOSCH   (South Africa)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g ABT ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESPONSE; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; NAMIBIA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PILL IDENTIFICATION TEST; RATING SCALE; SELF REPORT; VIRUS INHIBITION; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NAMIBIA; PATIENT COMPLIANCE; RNA, VIRAL;

EID: 84874526142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056307     Document Type: Article

References (38)

1. UNAIDS. (2012) Together We Will End AIDS. Available: http://www.unaids.org/en/resources/campaigns/togetherwewillendaids/index.html. Accessed 20 November 2012.
2. United Nations General Assembly. Sixty-Fifth Session. (2011) Political Declaration on HIV/AIDS: Intensifying our efforts to eliminate HIV/AIDS. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/document/2011/06/20110610_un_a-res-65-277_en.pdf. Accessed 28 March 2011.
3. Lucas GM, Chaisson RE, Moore RD, (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: 81-87.
4. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
5. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, et al. (2001) Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 33: 1417-1423.
6. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-573.
7. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS, (2007) HIV-Infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 45: 4-8.
8. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, et al. (2008) Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 rna viral load: a prospective cohort study. AIDS Res Hum Retroviruses 24: 1263-1268.
9. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20: 223-231.
10. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347.
11. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to aids. AIDS 15: 1181-1183.
12. Hogg RS, Heath K, Bangsberg DR, Yip B, Press N, et al. (2002) Intermittent use of triple combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16: 1051-1058.
13. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected south african adults. J Acquir Immune Defic Syndr 43: 78-84.
14. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, et al. (2006) Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts>Or = 200 cells/microl. AIDS 20: 1117-1123.
15. Roth HP, Caron HS, (1978) Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 3: 361-370.
16. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36(5): 1100-1102.
17. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB, (2006) Adherence to Antiretroviral Medication Among HIV-Positive Patients in Thailand. J Acquir Immune Defic Syndr 43: S119-S122.
18. Parienti JJ, Verdon R, Bazin C, Bouvet E, Massari V, et al. (2001) The pills identification test: a tool to assess adherence to antiretroviral therapy. JAMA 285(4): 412.
19. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 5: e109.
20. Goldman JD, Cantrell RA, Mulenga LB, Tambatamba BC, Reid SE, et al. (2008) Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses 24: 1031-1035.
21. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS, (2000) Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 23: 360-361.
22. The Republic of Namibia Ministry of Health and Social Services. (2010) Report of the 2010 National HIV Sentinel Survey. Windhoek, Namibia: MoHSS. Available: http://www.healthnet.org.na/documents/hiv_aids/National%20HIV%20Sentinel%20Survey%202010.pdf. Accessed 30 June 2012.
23. Central Intelligence Agency. (2009) "Namibia". The World Factbook. Available: https://www.cia.gov/library/publications/the-world-factbook/geos/wa.html. Accessed 28 March 2012.
24. Republic of Namibia Ministry of Health and Social Services Directorate of Special Programmes. (2010) National Guidelines for Antiretroviral Therapy. Third Edition. Available: http://www.healthnet.org.na/documents/hiv_aids/National%20Guideline%20for%20Antiretroviral%20Therapy-%203rd%20Edition.pdf. Accessed 18 October 2011.
25. WHO UNAIDS, UNICEF. (2011) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2011. Available: http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed 21 March 2012.
26. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, et al. (2011) Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 15 52(4): 493-506.
27. Khomas Region Census Indicators. (2012) Available: http://www.npc.gov.na/census/khomas_indicators.htm.Accessed 28 March 2012.
28. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D, (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 13 (Suppl 2): 15-23.
29. WHO. (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 28 March 2012.
30. The World Bank. (2012) Namibia. Available: http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/NAMIBIAEXTN/0,menuPK:382319~pagePK:141132~piPK:141109~theSitePK:382293,00.html. Accessed 12 January 2012.
31. Orrell C, Bangsberg DR, Badri M, Wood R, (2003) Adherence is not a barrier to successful antiretroviral therapy in south africa. AIDS 17: 1369-1375.
32. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, et al. (2004) Adherence to antiretroviral therapy in HIV-infected adults in soweto, south africa. AIDS Res Hum Retroviruses 20: 1053-1056.
33. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-saharan Africa and North America: A meta-analysis. JAMA 296: 679-690.
34. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, et al. (2006) Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 10: 227-245.
35. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38(9): 1311-1316.
36. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in kampala, uganda. AIDS 21(8): 965-971.
37. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, et al. (2011) Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr. 56(4): 356-64.
38. Luca D, Marazzi MC, Mancinelli S, Ceffa S, Doro Altan AM, et al. (2011) Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in Sub-Saharan Africa. Andrea. J Acquir Immune Defic Syndr Nov 30. [Epub ahead of print].